OrthoPediatrics Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

OrthoPediatrics wird ein Gewinn- und Umsatzwachstum von 22.6% bzw. 16.8% pro Jahr prognostiziert, während der Gewinn pro Aktie um 23.1% pro Jahr wachsen soll.

Wichtige Informationen

22.6%

Wachstumsrate der Gewinne

23.1%

EPS-Wachstumsrate

Medical Equipment Gewinnwachstum	17.2%
Wachstumsrate der Einnahmen	16.8%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	13 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

The OrthoPediatrics Corp. (NASDAQ:KIDS) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

Aug 09

OrthoPediatrics Corp. (NASDAQ:KIDS) Just Reported And Analysts Have Been Lifting Their Price Targets

May 09

Recent updates

Investors Still Waiting For A Pull Back In OrthoPediatrics Corp. (NASDAQ:KIDS)

Nov 05

The OrthoPediatrics Corp. (NASDAQ:KIDS) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

Aug 09

Shareholders Should Be Pleased With OrthoPediatrics Corp.'s (NASDAQ:KIDS) Price

Aug 02

OrthoPediatrics Corp. (NASDAQ:KIDS) Just Reported And Analysts Have Been Lifting Their Price Targets

May 09

OrthoPediatrics (NASDAQ:KIDS) Has Debt But No Earnings; Should You Worry?

May 07

Why Investors Shouldn't Be Surprised By OrthoPediatrics Corp.'s (NASDAQ:KIDS) P/S

Apr 10

Why Investors Shouldn't Be Surprised By OrthoPediatrics Corp.'s (NASDAQ:KIDS) P/S

Dec 20

Gewinn- und Umsatzwachstumsprognosen

NasdaqGM:KIDS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	282	-17	N/A	N/A	6
12/31/2025	240	-24	N/A	N/A	6
12/31/2024	203	-29	N/A	N/A	6
9/30/2024	190	-28	-51	-31	N/A
6/30/2024	175	-25	-51	-29	N/A
3/31/2024	162	-22	-48	-27	N/A
12/31/2023	149	-21	-46	-27	N/A
9/30/2023	142	-22	-35	-23	N/A
6/30/2023	137	1	-31	-20	N/A
3/31/2023	130	4	-35	-24	N/A
12/31/2022	122	1	-32	-22	N/A
9/30/2022	116	9	-32	-20	N/A
6/30/2022	106	-12	-33	-15	N/A
3/31/2022	100	-15	-31	-15	N/A
12/31/2021	98	-16	-30	-13	N/A
9/30/2021	92	-30	-30	-12	N/A
6/30/2021	89	-33	-27	-15	N/A
3/31/2021	76	-38	-26	-13	N/A
12/31/2020	71	-33	-30	-19	N/A
9/30/2020	71	-23	-34	-25	N/A
6/30/2020	70	-22	-31	-22	N/A
3/31/2020	74	-15	-32	-21	N/A
12/31/2019	73	-13	-30	-18	N/A
9/30/2019	68	-11	-24	-14	N/A
6/30/2019	63	-10	-24	-14	N/A
3/31/2019	60	-10	-22	-14	N/A
12/31/2018	58	-12	-21	-16	N/A
9/30/2018	55	-25	-23	-16	N/A
6/30/2018	51	-26	N/A	-15	N/A
3/31/2018	48	-26	N/A	-12	N/A
12/31/2017	46	-24	N/A	-7	N/A
9/30/2017	43	-14	N/A	-3	N/A
6/30/2017	41	-13	N/A	-3	N/A
3/31/2017	39	-12	N/A	1	N/A
12/31/2016	37	-12	N/A	-1	N/A
3/31/2016	33	-12	N/A	-2	N/A
12/31/2015	31	-13	N/A	-1	N/A
12/31/2014	24	-13	N/A	-10	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: KIDS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: KIDS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: KIDS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: KIDSDie Einnahmen des Unternehmens (16.8% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (9% pro Jahr).

Hohe Wachstumseinnahmen: KIDSDie Einnahmen des Unternehmens (16.8% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von KIDS in 3 Jahren voraussichtlich hoch sein wird

OrthoPediatrics Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

OrthoPediatrics Corp. Increases Earnings Guidance for the Full Year 2024

The OrthoPediatrics Corp. (NASDAQ:KIDS) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

Orthopediatrics Corp. Reiterates Revenue Guidance for the Year 2024

OrthoPediatrics Corp. (NASDAQ:KIDS) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target increased by 7.5% to US$43.00

OrthoPediatrics Corp. Revises Revenue Guidance for the Full Year 2024

Recent updates

OrthoPediatrics Corp. Increases Earnings Guidance for the Full Year 2024

Investors Still Waiting For A Pull Back In OrthoPediatrics Corp. (NASDAQ:KIDS)

OrthoPediatrics Corp. to Report Q3, 2024 Results on Nov 06, 2024

The OrthoPediatrics Corp. (NASDAQ:KIDS) Second-Quarter Results Are Out And Analysts Have Published New Forecasts

Orthopediatrics Corp. Reiterates Revenue Guidance for the Year 2024

Shareholders Should Be Pleased With OrthoPediatrics Corp.'s (NASDAQ:KIDS) Price

OrthoPediatrics Corp. to Report Q2, 2024 Results on Aug 05, 2024

New minor risk - Shareholder dilution

OrthoPediatrics Corp. (NASDAQ:KIDS) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target increased by 7.5% to US$43.00

OrthoPediatrics Corp. Revises Revenue Guidance for the Full Year 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

OrthoPediatrics (NASDAQ:KIDS) Has Debt But No Earnings; Should You Worry?

OrthoPediatrics Corp. Receives Breakthrough Device” Designation from FDA for eLLi Growing Rod System for Pediatric Patients with Scoliosis

OrthoPediatrics Corp. to Report Q1, 2024 Results on May 06, 2024

Why Investors Shouldn't Be Surprised By OrthoPediatrics Corp.'s (NASDAQ:KIDS) P/S

OrthoPediatrics Corp., Annual General Meeting, May 24, 2024

Consensus EPS estimates fall by 29%, revenue upgraded

President recently sold US$89k worth of stock

New major risk - Revenue and earnings growth

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Orthopediatrics Corp. Reiterates Revenue Guidance for Full Year 2024

Orthopediatrics Corp. Provides Revenue Guidance for Full Year 2024

OrthoPediatrics Corp. Launches New RESPONSE Rib and Pelvic Fixation System for EOS Scoliosis

Insider recently sold US$81k worth of stock

OrthoPediatrics Corp. to Report Q4, 2023 Results on Mar 06, 2024

OrthoPediatrics Corp. Provides Preliminary Unaudited Revenue Guidance Fourth Quarter and Full Year 2023 and for the Year 2024

Why Investors Shouldn't Be Surprised By OrthoPediatrics Corp.'s (NASDAQ:KIDS) P/S

OrthoPediatrics Corp. Reiterates Earnings Guidance for the Full Year of 2023

New minor risk - Profitability

Price target decreased by 16% to US$44.67

New minor risk - Shareholder dilution

OrthoPediatrics Corp. to Report Q3, 2023 Results on Nov 06, 2023

Price target decreased by 8.3% to US$50.00

OrthoPediatrics Corp. Launches DF2 Brace

OrthoPediatrics Corp. Reiterates Earnings Guidance for the Full Year of 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

OrthoPediatrics Corp. Announces the Launch and First Case Using the GIRO Growth Modulation System

Key Executive recently sold US$190k worth of stock

OrthoPediatrics Corp. Announces Election of George Dyer to its Board of Directors

OrthoPediatrics Corp. Announces Launch of Response Power Scoliosis System

Getting In Cheap On OrthoPediatrics Corp. (NASDAQ:KIDS) Might Be Difficult

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 21%

Insider recently sold US$112k worth of stock

Insider notifies of intention to sell stock

Full year 2022 earnings: EPS and revenues miss analyst expectations

OrthoPediatrics Corp. to Report Q4, 2022 Results on Feb 28, 2023

OrthoPediatrics Corp. Provides Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022 and Fiscal Year 2023

Less than half of directors are independent

OrthoPediatrics' (NASDAQ:KIDS) Earnings Aren't As Good As They Appear

Consensus forecasts updated

Price target decreased to US$57.33

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

OrthoPediatrics Corp. Updates Revenue Guidance for the Year 2022

Less than half of directors are independent

Orthopediatrics Corp. Announces Retirement of Stephen F. Burns from Board of Directors

OrthoPediatrics Corp. to Report Q3, 2022 Results on Oct 31, 2022

OrthoPediatrics Corp. has completed a Follow-on Equity Offering in the amount of $125.124619 million.

Consensus estimates of losses per share improve by 13%

OrthoPediatrics announces public offering of stock, pre-funded warrants

Is OrthoPediatrics (NASDAQ:KIDS) Using Debt In A Risky Way?

Price target increased to US$63.00

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

OrthoPediatrics Corp. Revises Revenue Guidance for the Year 2022

OrthoPediatrics Corp. to Report Q2, 2022 Results on Aug 03, 2022

OrthoPediatrics enters distribution agreement with 3D-Side

OrthoPediatrics Corp. (NasdaqGM:KIDS) and OrthoPediatrics Canada ULC completed the acquisition of Pega Medical Inc. for CAD 33 million.

OrthoPediatrics Corp. announced that it has received $50 million in funding from Squadron Capital, LLC